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SUMMARY 72 
Chronic liver disease due to alcohol use disorder contributes markedly to the global 73 
burden of disease and mortality1-3. Alcoholic hepatitis is a severe and life-threatening form 74 
of alcohol-associated liver disease. The gut microbiota promotes ethanol-induced liver 75 
disease in mice4, but little is known about microbial factors responsible for this process. 76 
We identified cytolysin, a two-subunit exotoxin secreted by Enterococcus faecalis (E. 77 
faecalis)5,6, to cause hepatocyte death and liver injury. Compared with controls, patients 78 
with alcoholic hepatitis have increased fecal numbers of E. faecalis. The presence of 79 
cytolysin-positive (cytolytic) E. faecalis correlated with liver disease severity and mortality 80 
in patients with alcoholic hepatitis. Using humanized mice colonized with bacteria from 81 
feces of patients with alcoholic hepatitis, we investigated the therapeutic effects of 82 
bacteriophages that target cytolytic E. faecalis.  We found these phages to decrease 83 
cytolysin in the liver and abolish ethanol-induced liver disease in humanized mice. Our 84 
findings link cytolysin-positive E. faecalis with worse clinical outcomes and mortality in 85 
patients with alcoholic hepatitis. We show that bacteriophages can specifically target 86 
cytolytic E. faecalis, providing a method to precisely edit the intestinal microbiota. A 87 
prospective clinical trial with a larger cohort is required to validate human relevance of 88 
our findings and to test whether this new therapeutic approach is effective for patients 89 
with alcoholic hepatitis.   90 
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MAIN  91 
The most severe form of alcohol-related liver disease is alcoholic hepatitis; mortality 92 
ranges from 20% to 40% at 1–6 months, and as many as 75% of patients die within 90 93 
days of a diagnosis of severe alcoholic hepatitis7-9. Therapy with corticosteroids is only 94 
marginally effective9. Early liver transplantation is the only curative therapy, but is offered 95 
only at select centers, to a limited group of patients10.  96 
Alcohol-related liver disease can be transmitted via fecal microbiota4. We 97 
investigated microbes and microbial factors responsible for this transmissible phenotype 98 
and for progression of alcohol-related liver disease. 99 
Cytolysin presence associates with increased mortality 100 
To determine whether chronic alcohol use and alcoholic hepatitis are associated with 101 
an altered composition of the fecal microbiota, 16S ribosomal RNA (rRNA) gene 102 
sequencing was performed. Differences in fecal microbiota composition were noted in 103 
patients with alcohol use disorder and alcoholic hepatitis, compared to subjects without 104 
alcohol use disorder (controls) (Fig. 1a; Extended Data Fig. 1a–1b; Supplementary Tables 105 
1 and 2). One significant difference we observed was an increase in the proportion of 106 
Enterococcus spp. In patients with alcoholic hepatitis, 5.59% of fecal bacteria were 107 
Enterococcus spp, compared with almost none in controls (0.023%; 0.004% of all reads 108 
in the Human Microbiome Project) or patients with alcohol use disorder (0.024%). Fecal 109 
samples from patients with alcoholic hepatitis had about 2,700-fold more Enterococcus 110 
faecalis (E. faecalis) than samples from controls, measured by quantitative PCR (qPCR) 111 
(Extended Data Fig. 1c), consistent with 16S rRNA sequencing results. About 80% of 112 
alcoholic hepatitis patients are E. faecalis positive in feces (Extended Data Fig. 1d).  113 
Colonization of mice with E. faecalis induces mild hepatic steatosis and exacerbates 114 
ethanol-induced liver disease11 by unclear mechanisms. Cytolysin is a bacterial exotoxin 115 
(bacteriocin) produced by E. faecalis12 that contains two post-translationally modified 116 
peptides, CylLL” and CylLS”, in its bioactive form6. The two peptides are encoded by two 117 
separate genes, cylLL and cylLS12. Cytolysin has lytic activity against not only Gram-118 
positive bacteria but also eukaryotic cells13. We detected cylLL and cylLS genomic DNA 119 
(cytolysin-positive) in fecal samples from 30% of patients with alcoholic hepatitis; none of 120 
the fecal samples from controls and only one sample from a patient with alcohol use 121 
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disorder was cytolysin-positive, detected by qPCR (Fig. 1b). Importantly, 89% of cytolysin-122 
positive patients with alcoholic hepatitis died within 180 days after admission compared 123 
to only 3.8% of cytolysin-negative patients (P<0.0001) (Fig. 1c). Among those cytolysin-124 
positive patients, 72.2% died due to liver failure (including liver failure related 125 
complications such as gastrointestinal bleeding) (Supplementary Table 2). Infection was 126 
not associated with 30-day, 90-day or 180-day mortality (P=0.403, 0.234 or 0.098) in 127 
patients with alcoholic hepatitis. 128 
Univariate logistic and Cox regression of laboratory and clinical parameters 129 
associated detection of cytolysin-encoding genes in feces with international normalized 130 
ratio (INR), platelet count, model for end-stage liver disease (MELD) score, sodium MELD 131 
(MELDNa) score, age, serum bilirubin, INR, and serum creatinine (ABIC) score, and 132 
death (Supplementary Table 3). In the multivariate Cox analysis, detection of cytolysin-133 
encoding genes in feces was still associated with 90-day (P=0.004) or 180-day mortality 134 
(P=0.001) (Supplementary Table 3), after we adjusted for the geographic origin of the 135 
patients; antibiotic treatment; platelet count; and creatinine, bilirubin, and INR as 136 
components of the MELD score. We found no serious multicollinearity between detection 137 
of fecal cytolysin and these cofactors (variance inflation factor (VIF) <1.6), indicating that 138 
cytolysin is an independent predictor of mortality in patients with alcoholic hepatitis. When 139 
we performed receiver operating characteristic (ROC) curve analysis for 90-day mortality, 140 
cytolysin had an AUC of 0.81, which was superior to other widely used predictors for 141 
mortality in clinical practice (Extended Data Fig. 1e). Based on our findings, we propose 142 
that the detection of cytolysin may be a prognostic factor for worse liver-related outcomes 143 
and death, and a stronger predictor of mortality than MELD, ABIC, and discriminant 144 
function (DF).   145 
To determine phylogeny of E. faecalis in patients with alcoholic hepatitis, we 146 
performed targeted culturing from stool samples. Whole-genome sequencing of 93 E. 147 
faecalis isolates revealed broad phylogenetic diversity of cytolysin-positive E. faecalis 148 
from patients with alcoholic hepatitis (Fig. 1d), indicating that cytolysin production is a 149 
variable trait among E. faecalis isolates and that cytolysin is carried in mobile (genetic) 150 
elements, which include both chromosomally-encoded pathogenicity islands (PAI) and 151 
plasmids14. Detection of any other antimicrobial resistance genes or virulence genes in 152 
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E. faecalis isolates did not correlate with disease severity or mortality in patients with 153 
alcoholic hepatitis (Supplementary Table 4). 154 
The total amount of fecal E. faecalis or fecal E. faecalis positivity did not correlate 155 
with disease severity or mortality in patients with alcoholic hepatitis (Supplementary 156 
Tables 5 and 6). Cytolysin-positive and cytolysin-negative patients with alcoholic hepatitis 157 
had similar amounts of fecal E. faecalis (Extended Data Fig. 1f). Although there were 158 
differences in the composition of the gut microbiota in patients with alcoholic hepatitis 159 
from different geographic regions (Extended Data Fig. 1g), the proportion of cytolysin-160 
positive patients, total amount of fecal E. faecalis, fecal E. faecalis positivity (Extended 161 
Data Fig. 1h–1j), treatment, and clinical outcomes (30 day and 90 day mortality) did not 162 
differ significantly among the regions/centers (Supplementary Table 7). In addition, 163 
cirrhosis was not associated with cytolysin-positivity, the total amount of fecal E. faecalis, 164 
or fecal E. faecalis positivity in alcoholic hepatitis patients (Extended Data Fig. 1k–1m; 165 
Supplementary Tables 4–6). These results confirm our findings that the presence of 166 
cytolysin producing E. faecalis, rather than the total amount or presence of E. faecalis, 167 
determines the severity of alcoholic hepatitis and mortality. 168 
Cytolysin promotes ethanol-induced liver disease 169 
To determine whether cytolysin contributes to liver damage mediated by E. faecalis, 170 
we gavaged mice with a cytolytic E. faecalis strain (FA2-2(pAM714)) or a non-cytolytic E. 171 
faecalis strain (FA2-2(pAM771))5; the mice were then placed on a chronic–binge ethanol 172 
diet15. Compared to mice given phosphate-buffered saline (PBS), mice fed ethanol after 173 
they were gavaged with cytolytic E. faecalis developed more severe liver injury, indicated 174 
by higher level of alanine amino-transferase (ALT) (Extended Data Fig. 2a) and increased 175 
hepatic steatosis (Extended Data Fig. 2b and 2c). Mice fed ethanol after they were 176 
gavaged with cytolytic E. faecalis also had more liver inflammation with higher expression 177 
levels of mRNAs encoding inflammatory cytokines and chemokines (Il1b, Cxcl1, and 178 
Cxcl2) (Extended Data Fig. 2d–2f) compared with mice given PBS. Mice fed ethanol after 179 
they were gavaged with non-cytolytic E. faecalis had significantly less ethanol-induced 180 
liver injury, steatosis, and inflammation (Extended Data Fig. 2a–2f) and longer survival 181 
times (Extended Data Fig. 2g), compared with mice fed ethanol after they were 182 
administered cytolytic E. faecalis.  183 
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To explore the mechanism of cytolysin-associated liver damage, we measured 184 
cytolysin in the liver. CylLS was significantly increased in livers of mice given cytolytic E. 185 
faecalis but not mice that were not given E. faecalis or mice gavaged with non-cytolytic 186 
E. faecalis following chronic ethanol administration (Extended Data Fig. 2h). E. faecalis 187 
was detectable in the liver of mice given cytolytic and non-cytolytic E. faecalis and fed an 188 
ethanol diet, but not when fed an isocaloric (control) diet (Extended Data Fig. 2i), 189 
indicating that ethanol-induced changes in the gut barrier are necessary for translocation 190 
of cytolytic E. faecalis from the intestine to the liver. Livers of ethanol-fed mice given 191 
cytolytic and non-cytolytic E. faecalis had positive E. faecalis cultures (Extended Data Fig. 192 
2j). We observed increased intestinal permeability in ethanol-fed mice compared with 193 
isocaloric diet-fed mice, but this was independent of gavaging cytolytic or non-cytolytic E. 194 
faecalis following chronic ethanol administration (Extended Data Fig. 2k), indicating that 195 
cytolysin does not affect intestinal barrier function.  196 
Administration of cytolytic or non-cytolytic E. faecalis to mice did not significantly 197 
change the composition of the intestinal microbiota, based on 16S rRNA gene sequencing 198 
(Extended Data Fig. 2l). Cytolytic E. faecalis did not affect intestinal absorption or hepatic 199 
metabolism of ethanol, based on serum levels of ethanol and hepatic levels of Adh1 and 200 
Cyp2e1 mRNAs (encoding the two primary enzymes that metabolize ethanol in the liver) 201 
(Extended Data Fig. 2m and 2n). These results indicate that E. faecalis that produce 202 
cytolysin promote ethanol-induced liver disease in mice.  203 
To extend our findings to humans, we colonized germ-free mice with feces from 204 
cytolysin-positive and -negative patients with alcoholic hepatitis (Supplementary Table 8). 205 
Consistent with our findings from mice colonized with cytolytic E. faecalis, gnotobiotic 206 
C57BL/6 mice colonized with feces from two different cytolysin-positive patients 207 
developed more severe ethanol-induced liver injury, steatosis, inflammation, and fibrosis 208 
than mice given feces from two different cytolysin-negative patients (Fig. 2a–2f; Extended 209 
Data Fig. 3a–3d). Transplantation of feces from cytolysin-positive patients reduced 210 
survival time of the mice (Extended Data Fig. 3e) and increased translocation of cytolytic 211 
E. faecalis to the liver following ethanol administration (Fig. 2g). Overall composition of 212 
the intestinal microbiota was not different between mice colonized with feces from 213 
cytolysin-positive or -negative alcoholic hepatitis donors following the control diet, based 214 
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on 16S rRNA gene sequencing. Mice transplanted with feces from one cytolysin-positive 215 
alcoholic hepatitis patient (#2) showed a microbiota significantly different from the other 216 
mouse groups following ethanol administration (Extended Data Fig. 3f). Interestingly, non-217 
cytolytic E. faecalis was not detected in stool samples from donors with cytolytic E. 218 
faecalis (Extended Data Fig. 3g). We did not observe differences in intestinal absorption 219 
or hepatic metabolism of ethanol between mice colonized with feces from cytolysin-220 
positive vs cytolysin-negative patients (Extended Data Fig. 3h and 3i). Together, these 221 
results provide further evidence that cytolysin promotes ethanol-induced liver disease. 222 
To determine the mechanism by which cytolysin increases liver disease, we isolated 223 
hepatocytes from mice on ethanol or control diets and stimulated them with pure bioactive 224 
cytolysin peptides (CylLL” and CylLS”)6. Incubation of the primary mouse hepatocytes with 225 
two cytolysin subunits caused a dose-dependent increase in cell death compared to 226 
hepatocytes incubated with vehicle or with one subunit alone (Fig. 2h). Interestingly, when 227 
we isolated hepatocytes from ethanol-fed mice and then incubated those hepatocytes 228 
with ethanol, we did not observe increased levels of cytolysin-induced cell death 229 
compared to hepatocytes isolated from mice on the control diet, indicating that cytolysin-230 
induced hepatocyte cell death was independent of ethanol. The cytotoxic effects of 231 
cytolysin are likely mediated by pore formation, resulting in cell lysis14.  232 
Bacteriophage treatment attenuates alcohol-related liver disease in mice 233 
To further demonstrate the potential causative role of cytolytic E. faecalis for the 234 
development of ethanol-induced steatohepatitis, we investigated the effects of treatment 235 
with bacteriophages. Bacteriophages (phages) are ubiquitous in bacteria-rich 236 
environment, including the gut16. E. faecalis phages that are highly-strain specific can be 237 
isolated17, potentially making direct editing of gut microbiota feasible. We have shown 238 
that Atp4aSl/Sl mice, which lack gastric acid, have overgrowth of intestinal enterococci, 239 
associated with increased susceptibility to alcohol-induced steatohepatitis11. Gavaging of 240 
wild-type mice with an E. faecalis strain isolated from Atp4aSl/Sl mice increased ethanol-241 
induced steatohepatitis11. We found that this E. faecalis strain expressed cytolysin. We 242 
then isolated four distinct bacteriophages from sewage water. These bacteriophages lyse 243 
the cytolytic E. faecalis strain isolated from Atp4aSl/Sl mice. All four phages were 244 
podophages of the virulent Picovirinae group (Extended Data Fig. 4). Atp4aSl/Sl mice and 245 
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their wild-type littermates were then placed on the chronic–binge ethanol diet and 246 
gavaged with the lytic bacteriophage cocktail (Extended Data Fig. 5). Bacteriophages 247 
directed against Caulobacter crescentus (C. crescentus), a bacterium that is present in 248 
fresh water lakes and streams18, but does not colonize humans or rodents19,20, were used 249 
as controls. Compared to Atp4aSl/Sl mice gavaged with control bacteriophage or vehicle, 250 
Atp4aSl/Sl mice gavaged with bacteriophages that target cytolytic E. faecalis had less liver 251 
injury, steatosis, and inflammation following chronic ethanol feeding (Extended Data Fig. 252 
5a–5f). Administration of E. faecalis bacteriophage significantly reduced levels of 253 
cytolysin in the liver (Extended Data Fig. 5g) and fecal amounts of Enterococcus 254 
(Extended Data Fig. 5h). Bacteriophage administration did not affect the overall 255 
composition of the fecal microbiome, intestinal absorption or hepatic metabolism of 256 
ethanol (Extended Data Fig. 5i–5k). 257 
To develop a novel therapeutic approach to precisely edit the intestinal microbiota, 258 
cytolytic E. faecalis strains were cultured from fecal samples of patients with alcoholic 259 
hepatitis. We then isolated lytic bacteriophages from sewage water against these cytolytic 260 
E. faecalis strains and these phages had siphophage or myophage morphology (Fig. 3a; 261 
Extended Data Fig. 6). Gnotobiotic mice were colonized with feces from two different 262 
cytolysin-positive patients with alcoholic hepatitis (Supplementary Table 8) and given 3–263 
4 different, but patient-specific lytic phages against cytolytic E. faecalis. The phages 264 
against cytolytic E. faecalis abolished ethanol-induced liver injury and steatosis, based 265 
on lower levels of ALT, percentage of TUNEL-positive hepatic cells, hepatic triglycerides 266 
and oil red O-staining (Fig. 3b–3d; Extended Data Fig. 7a–7b), decreased hepatic levels 267 
of Il1b, Cxcl1, Cxcl2, Col1a1 and Acta2 mRNAs, and reduced hepatic levels of cylLs, 268 
compared with mice given control phages (against C. crescentus) (Fig. 3e–3h; Extended 269 
Data Fig. 7c–7d). Treatment with phages against cytolytic E. faecalis also reduced fecal 270 
amounts of Enterococcus (Extended Data Fig. 7e) without affecting the overall 271 
composition of the gut microbiota (Extended Data Fig. 7f). Intestinal absorption of ethanol 272 
and hepatic metabolism were similar in all groups (Extended Data Fig. 7g–7h).  273 
To demonstrate that the effect of bacteriophage treatment occurs via targeting of 274 
cytolysin-positive E. faecalis, rather than reduction in cytolysin-negative E. faecalis, we 275 
colonized gnotobiotic mice with feces from cytolysin-negative patients with alcoholic 276 
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hepatitis (Supplementary Table 8). Bacteriophages against non-cytolytic E. faecalis from 277 
patients were isolated from sewage water, and they had siphophage or podophage 278 
morphology (Fig. 4a; Extended Data Fig. 8). These phages did not reduce features of 279 
ethanol-induced liver disease compared with control phages (Fig. 4b–4g; Extended Data 280 
Fig. 9a–9h), despite the reduction of fecal Enterococcus (Fig. 4h). Our findings indicate 281 
that lytic bacteriophage treatment can selectively attenuate ethanol-induced liver disease 282 
caused by cytolysin-positive E. faecalis in humanized mice. 283 
Discussion 284 
Phage-based therapies have been studied predominantly in patients with bacterial 285 
infections in the gastrointestinal tract21-23, urinary tract24,25 and other organ systems26-28. 286 
The results of these studies, while mixed in terms of efficacy, strongly suggest that phage 287 
treatment offers a safe alternative to antibiotics26,27. However, safety studies are required 288 
for complex populations such as patients with alcoholic hepatitis, since phages can 289 
induce a strong immune reaction29. Future work is required to determine if bacteriophages 290 
that target cytolytic E. faecalis might be used to treat patients with alcoholic hepatitis, a 291 
life-threatening disease with no effective treatment. Our data also suggest that cytolysin 292 
may be used as a predictive biomarker of severe alcoholic hepatitis; So an independent, 293 
prospective cohort is now needed to validate cytolysin as a biomarker and to extend the 294 
bacteriophage findings to human patients. 295 
Eradication of this specific bacterial strain might produce better outcomes than 296 
current treatments. Remarkably, environmental sources can be used to easily isolate 297 
phages that target cytolysin-positive E. faecalis. We provide the first example of the 298 
efficacy of phage-based approaches in mice for a disease that is not considered a classic 299 
infectious disease. A clinical trial with a larger cohort is required to validate human 300 
relevance of our findings and to test this new therapeutic approach for patients with 301 
alcoholic hepatitis.     302 
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Figure Legends 410 
Figure 1. E. faecalis cytolysin associates with mortality in patients with alcoholic 411 
hepatitis.  412 
(a) 16S rRNA sequencing of fecal samples from controls (n=14), patients with alcohol use 413 
disorder (AUD; n=43), or alcoholic hepatitis (n=75). Principal coordinate analysis (PCoA) 414 
based on Jaccard dissimilarity matrices was used to show ß-diversity among groups, at 415 
the genus level. Composition of fecal microbiota was significantly different between each 416 
group (P<0.01). (b) Percentage of subjects with fecal samples positive for cylLL and cylLS 417 
DNA sequences (cytolysin-positive), in controls (n=25), patients with AUD (n=38), or 418 
alcoholic hepatitis (n=82), assessed by qPCR. Statistically significant differences were 419 
detected between controls and alcoholic hepatitis patients (P<0.01), and between 420 
patients with alcohol use disorder and alcoholic hepatitis patients (P<0.001). (c) Kaplan-421 
Meier curve of survival of patients with alcoholic hepatitis whose fecal samples were 422 
cytolysin-positive (n=25) or cytolysin-negative (n=54) (P<0.0001). (d) Core genome single 423 
nucleotide polymorphism (SNP) tree of E. faecalis strains isolated from patients with 424 
alcoholic hepatitis (n=93 from 24 patients), showing phylogenetic diversity of cytolysin-425 
positive (red) E. faecalis. Genomically identical isolates from the same patient were 426 
combined and are shown as one single dot. Scale bar represents the nucleotide 427 
substitutions per SNP site. P values are determined by permutational multivariate 428 
analysis of variance (PERMANOVA) followed by false discovery rate (FDR) procedures 429 
(a), two-sided Fisher’s exact test followed by FDR procedures (b), or two-sided Log-rank 430 
(Mantel-Cox) test (c). The exact group size (n) and P values for each comparison are 431 
listed in Supplementary Table 10. 432 
 433 
Figure 2. Transplantation of feces from cytolysin-positive patients with alcoholic 434 
hepatitis exacerbates ethanol-induced liver disease in gnotobiotic mice. 435 
(a–g) C57BL/6 germfree mice were colonized with feces from two different cytolysin-436 
positive and two different cytolysin-negative patients with alcoholic hepatitis and 437 
subjected to the chronic–binge feeding model. (a) Serum levels of ALT. (b) Hepatic 438 
triglyceride content. (c) Representative H&E-stained liver sections. (d–f) Hepatic levels of 439 
mRNAs encoding Il1b, Cxcl1, and Col1a1. (g) Proportions of mice positive for cytolysin in 440 
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liver, measured by qPCR for cylLS. (h) LDH assay to measure cytotoxicity of hepatocytes 441 
isolated from mice fed oral isocaloric (control) diet (5 groups, left) or chronic–binge 442 
ethanol diet (5 groups, right) and incubated with vehicle, CylLS”, CylLL”, or both cytolysin 443 
subunits, at indicated concentrations, without (–) or with (+) ethanol (25mM) for 3 hours. 444 
Survival of hepatocytes was determined in 3 independent experiments. Scale bar=100 445 
μm. Results are expressed as mean ± s.e.m (a, b, d–f, h). P values are determined by 446 
One-way ANOVA with Tukey´s post-hoc test (a, b, d–f), two-sided Fisher’s exact test 447 
followed by FDR procedures (g), or Two-way ANOVA with Tukey´s post-hoc test (h). All 448 
results were generated from at least three independent replicates. The exact group size 449 
(n) and P values for each comparison are listed in Supplementary Table 10. *P<0.05, 450 
**P<0.01, ***P<0.001, ****P<0.0001. 451 
 452 
Figure 3. Phage therapy against cytolytic E. faecalis abolishes ethanol-induced 453 
liver disease in gnotobiotic mice.  454 
(a) Transmission electron microscopy revealed that bacteriophages isolated were either 455 
siphophages (Ef5.1, Ef5.2, Ef5.3, Ef5.4 and Ef2.2) or myophages (Ef2.1 and Ef2.3). Scale 456 
bar=50 nm. (b–h) C57BL/6 germfree mice were colonized with feces from two different 457 
cytolysin-positive patients with alcoholic hepatitis (feces from 1 patient also used in Figure 458 
2) and subjected to chronic–binge feeding model, gavaged with control phages against 459 
C. crescentus (1010 PFUs), or a cocktail of 3 or 4 different phages targeting cytolytic E. 460 
faecalis (1010 PFUs) 1 day before an ethanol binge. (b) Serum levels of ALT. (c) Hepatic 461 
triglyceride content. (d) Representative H&E-stained liver sections. Scale bar=100 μm. 462 
(e–g) Hepatic levels of mRNAs encoding Il1b, Cxcl1 and Col1a1. (h) Proportions of mice 463 
positive for cytolysin in liver, measured by qPCR for cylLS. Results are expressed as mean 464 
± s.e.m (b, c, e–g). P values are determined by Two-way ANOVA with Tukey´s post-hoc 465 
test (b, c, e–g) or two-sided Fisher’s exact test followed by FDR procedures (h). All results 466 
are generated from at least three independent replicates. The exact group size (n) and P 467 
values for each comparison are listed in Supplementary Table 10. *P<0.05, **P<0.01, *** 468 
P<0.001. 469 
 470 
Figure 4. Phages that target non-cytolytic E. faecalis do not reduce ethanol-induced 471 
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liver disease in gnotobiotic mice.  472 
(a) Transmission electron microscopy revealed that bacteriophages isolated were either 473 
podophages (Ef6.2, Ef6.3, Ef7.2, Ef7.3 and Ef7.4) or siphophages (Ef6.1, Ef6.4 and 474 
Ef7.1). Scale bar=50 nm. (b–h) C57BL/6 germfree mice were colonized with feces from 475 
two different cytolysin-negative patients with alcoholic hepatitis and subjected to chronic–476 
binge feeding model, gavaged with control phages against C. crescentus (1010 PFUs), or 477 
a cocktail of 4 different phages targeting non-cytolytic E. faecalis (1010 PFUs) 1 day before 478 
an ethanol binge. (b) Serum levels of ALT. (c) Hepatic triglyceride content. (d) 479 
Representative H&E-stained liver sections. Scale bar=100 μm. (e–g) Hepatic levels of 480 
mRNAs encoding Il1b, Cxcl1, and Col1a1. (h) Fecal colony forming units (CFUs) of 481 
Enterococcus. Results are expressed as mean ± s.e.m (b, c, e–h). P values are 482 
determined by Two-way ANOVA with Tukey´s post-hoc test (b, c, e–h). All results were 483 
generated from at least three independent replicates. The exact group size (n) and P 484 
values for each comparison are listed in Supplementary Table 10. *P<0.05.     485 
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Methods 486 
Patient cohorts. Patient cohorts have been described30-32. We evaluated 26 subjects 487 
without alcohol use disorder (controls; social drinkers consuming less than 20 g/day), 44 488 
patients with alcohol use disorder, and 88 patients with alcoholic hepatitis. Patients with 489 
alcohol use disorder fulfilling the DSM IV criteria33 of alcohol dependence and with active 490 
alcohol consumption (self-reported > 60 g/day) presented with various stages of liver 491 
disease (21% had advanced F3/4 fibrosis based on fibrosis-4 index (FIB-4); 492 
Supplementary Table 1). Patients with alcohol use disorder were recruited from an 493 
alcohol withdrawal unit in San Diego, USA and Brussels, Belgium where they followed a 494 
detoxification and rehabilitation program. At admission to the hospital, a complete 495 
medication and medical history is taken, and a complete physical examination is 496 
performed, including collection of biospecimens, basic demographic data, such as age, 497 
gender, weight and height, and self-reported daily alcohol consumption. Patients were 498 
actively drinking until the day of admission. Controls or patients with alcohol use disorder 499 
did not take antibiotics or immunosuppressive medication during the two months 500 
preceding enrollment. Other exclusion criteria were diabetes, inflammatory bowel 501 
disease, known liver disease of any other etiology, and clinically significant cardio-502 
vascular, pulmonary or renal co-morbidities. Alcoholic hepatitis patients were enrolled 503 
from the InTeam Consortium (ClinicalTrials.gov identifier number: NCT02075918) from 504 
centers in the USA, Mexico, United Kingdom, France and Spain. Inclusion criteria were 505 
active alcohol abuse (> 50 g/day for men and > 40 g/day for women) in the last 3 months, 506 
aspartate aminotransferase (AST) > alanine aminotransferase (ALT) and total bilirubin > 507 
3 mg/dl in the past 3 months, liver biopsy and/or clinical picture consistent with alcoholic 508 
hepatitis. Exclusion criteria were autoimmune liver disease (ANA > 1/320), chronic viral 509 
hepatitis, hepatocellular carcinoma, complete portal vein thrombosis, extrahepatic 510 
terminal disease, pregnancy, and lack of signed informed consent. In all patients, the 511 
clinical picture was consistent with alcoholic hepatitis and in patients who underwent liver 512 
biopsy, the histology was in line with the diagnosis of alcoholic hepatitis. Liver biopsies 513 
were only done if clinically indicated as part of routine clinical care for diagnostic purposes 514 
of alcoholic hepatitis. Biospecimens were collected during their admission to the hospital. 515 
The median time of specimen collection was 4 days following admission to the hospital 516 
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(range 0-24, n=82). For one patient who underwent liver transplantation, the 517 
transplantation date was considered as date of death. Patients were censored at the time 518 
point they were last seen alive. The baseline characteristics are shown in Supplementary 519 
Tables 1 and 2. Fecal 16S rRNA sequencing, Enterococcus culture and qPCR were 520 
performed. The MELD score, ABIC score and DF were calculated from all alcoholic 521 
hepatitis patients from whom respective laboratory values were available. The protocol 522 
was approved by the Ethics Committee of Hôpital Huriez (Lille, France), Universidad 523 
Autonoma de Nuevo Leon (Monterrey, México), Hospital Universitari Vall d'Hebron 524 
(Barcelona, Spain), King's College London (London, UK), Yale University (New Haven, 525 
USA), University of North Carolina at Chapel Hill (Chapel Hill, USA), Weill Cornell Medical 526 
College (New York,  USA),  Columbia University (New York, USA), University of 527 
Wisconsin (Madison, USA), VA San Diego Healthcare System (San Diego, USA), 528 
University of California San Diego (La Jolla, USA) and Université Catholique de Louvain 529 
(Brussels, Belgium). Patients were enrolled after written informed consent was obtained 530 
from each patient. 531 
 532 
Mice. C57BL/6 mice were purchased from Charles River and used in Figure 2h and 533 
Extended Data Figure 2. C57BL/6 germ-free mice were bred at UCSD and used in Figure 534 
2a-2g, Figure 3, Figure 4, Extended Data Figure 3, Extended Data Figure 7, and Extended 535 
Data Figure 9. Sublytic Atp4aSl/Sl mice on a C57BL/6 background have been 536 
described11,34 and heterozygous mice were used for breeding; sublytic Atp4aSl/Sl littermate 537 
mice and their wild-type littermates were used in Extended Data Figure 5.  538 
Female and male mice (age, 9–12 weeks) were placed on a chronic–binge ethanol 539 
diet (NIAAA model) as described15. Mice were fed with Lieber-DeCarli diet and the caloric 540 
intake from ethanol was 0% on days 1–5 and 36% from day 6 until the end of the study 541 
period. At day 16, mice were gavaged with a single dose of ethanol (5 g/kg body weight) 542 
in the early morning and sacrificed 9 hours later. Pair-fed control mice received a diet with 543 
an isocaloric substitution of dextrose. 544 
Stool samples from patients with alcoholic hepatitis (see Figure 1) were used for fecal 545 
transplantation in germ-free mice. Mice were gavaged with 100 μl of stool samples (1 g 546 
stool dissolved in 30 ml Luria-Bertani (LB) medium containing 15% glycerol under 547 
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anaerobic conditions), starting at an age of 5–6 weeks and repeated two weeks later. Two 548 
weeks after the second gavage, mice were placed on the ethanol or control (isocaloric) 549 
diet. 550 
In studies of the effects of cytolysin, 5 × 108 colony forming units (CFUs) of a cytolytic 551 
E. faecalis strain (FA2-2(pAM714)), a non-cytolytic E. faecalis strain (FA2-2(pAM771))5 552 
(E. faecalis cytolysin) (kindly provided by Dr. Michael S. Gilmore), or PBS (vehicle 553 
control) were fed to mice by gavage every third day, starting from day 6 through day 15 554 
of ethanol feeding (see above). Administration every third day was necessary, given that 555 
E. faecalis does not colonize mice11 (Extended Data Fig. 2o). To determine the effect of 556 
bacteriophage treatment, 1010 plaque forming units (PFUs) E. faecalis phages (or C. 557 
crescentus phage phiCbK as control)35 were gavaged to the mice one day before the 558 
ethanol binge (at day 16). All animal studies were reviewed and approved by the 559 
Institutional Animal Care and Use Committee of the University of California, San Diego. 560 
 561 
Bacteriophages isolation and amplification. E. faecalis strain from Atp4aSl/Sl mice 562 
feces was isolated before11 and was used to isolate phages Efmus1, Efmus2, Efmus3 563 
and Efmus4. E. faecalis strains from human stool samples were isolated using methods 564 
described below and the corresponding phages were named as Ef with patient number 565 
plus a digit (Ef for E. faecalis, last digit for isolation order). All E. faecalis strains were 566 
grown statically in brain heart infusion (BHI) broth or on BHI agar at 37°C. C. crescentus 567 
phage phiCbK was purified as previously described35. 568 
E. faecalis phages were isolated from untreated raw sewage water obtained from 569 
North City Water Reclamation Plant in San Diego, California. Fifty milliliter raw sewage 570 
water was centrifuged at 8,000 x g for 1 min at room temperature (RT) to pellet large 571 
particles. The supernatant was passed through a 0.45 μm and then a 0.2 μm syringe filter 572 
(Whatman, PES membrane). One hundred microliter of the clarified sewage was mixed 573 
with 100 μl overnight E. faecalis culture and then added to BHI broth top agar (0.5% agar) 574 
and poured over a BHI plate (1.5% agar). After overnight growth at 37°C, the resulting 575 
plaques were recovered using a sterile pipette tip in 500 μl PBS. Phages were replaqued 576 
on E. faecalis three more times to ensure that the phages were clonal isolates.  577 
High-titer phage stocks were propagated by infecting 200 ml of exponentially growing 578 
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E. faecalis at a multiplicity of infection (MOI) of 0.1 in BHI broth containing 10 mM MgSO4. 579 
Lysis was allowed to proceed for up to six hours at 37°C with shaking. The lysates were 580 
centrifuged at 10,000 x g for 20min at RT to remove the remaining bacterial cells and 581 
debris. Supernatant was then vacuum filtered through a 0.2 μm membrane filter and kept 582 
at 4°C until use.  583 
Before mice were gavaged, 10–20 ml lysates were concentrated using Corning Spin-584 
X UF Concentrators with 100,000-molecular-weight-cutoff (MWCO) to a volume of 585 
approximately 1 ml. Following concentration, the culture medium was replaced with PBS 586 
via diafiltration. The resulting lysate was further concentrated to a final volume of 0.5 ml 587 
and adjusted to the required PFUs. 588 
 589 
Whole-genome sequencing for bacteriophages. For all phages except Efmus4, 10 ml 590 
of lysates were treated with 10 μg/ml each of DNase and RNase at 37°C for 1 hour and 591 
phages were precipitated by adding 1M NaCl and 10% (w/v) polyethylene glycol 8000 592 
(PEG 8000) and incubated at 4°C overnight. Precipitated phages were then pelleted by 593 
centrifugation at 10,000 x g for 10 min at 4°C and resuspended in 500 μl of resuspension 594 
buffer (5 mM MgSO4). Phage DNA was then extracted using Promega Wizard DNA 595 
Clean-up kit (Promega). Phage genomes were sequenced using a combination of 596 
Illumina and Oxford Nanopore Technologies (ONT) MinION platforms. Illumina 597 
sequencing libraries were prepared using the Nextera XT library kit with bead-based size 598 
selection prior to loading onto Illumina flow cells. Sequencing was performed with either 599 
Illumina MiSeq Reagent Kit v3 in 2 × 300-bp or NextSeq 500 Mid Output Kit in 2 × 150-600 
bp paired-end formats. ONT MinION sequencing libraries were prepared using the Rapid 601 
Barcoding Kit (SQK-RBK004) and loaded onto MinION R9.4 flow cells. ONT reads were 602 
basecalled with Albacore v2.3.4 (ONT). The sequence reads were demultiplexed and 603 
adapters trimmed from ONT reads using Porechop v0.2.336. A hybrid Illumina-ONT de 604 
novo assembly was performed using the Unicycler v0.4.7 pipeline37. Subsequently, Pilon 605 
v1.2238 was used iteratively to polish the assemblies with Illumina reads until no additional 606 
corrections could be made.  607 
For phage Efmus4, 109 PFUs of the phage was filtered sequentially using 0.45 μm 608 
and 0.2 μm filters (VWR) and purified on a cesium chloride (CsCl) density gradient39. One 609 
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milliliter of the CsCl fraction was purified on Amicon YM-100 protein columns (Millipore) 610 
and treated with DNase I. DNA was isolated using a Qiagen UltraSens virus kit (Qiagen), 611 
amplified using GenomiPhi V2 (GE Healthcare), and fragmented to 200 to 400 bp using 612 
a Bioruptor (Diagenode). Libraries were created using the Ion Plus fragment library kit 613 
and sequenced using a 316 Chip on an Ion Torrent Personal Genome Machine (Life 614 
Technologies). Reads were trimmed according to modified Phred scores of 0.5 using CLC 615 
Genomics Workbench 4.9 (Cambridge), and the remaining reads were assembled using 616 
CLC Genomics Workbench 4.9 based on 98% identity with a minimum of 50% read 617 
overlap39. Reads were assembled into a single contig of 18,186 bp (20,118 x coverage). 618 
Mapping of ONT reads to the hybrid assemblies was used to determine the orientation 619 
and terminal ends of linear phage genomes while reference genomes served as guides 620 
to orient circular phage genomes. Phage genome assemblies were annotated using the 621 
NCBI Prokaryotic Genome Annotation Pipeline (PGAP)40,41.  622 
Phage raw sequence reads and annotated genomes are available at NCBI under the 623 
following consecutive BioSample IDs (SAMN11089809– SAMN11089827). GenBank 624 
accession numbers include: Efmus1 (MK721195), Efmus2 (MK721197), Efmus3 625 
(MK721185), Efmus4 (MK721193), Ef2.1 (MK693030), Ef2.2 (MK721189), Ef2.3 626 
(MK721192), Ef5.1 (MK721199), Ef5.2 (MK721186), Ef5.3 (MK721200), Ef5.4 627 
(MK721191), Ef6.1 (MK721187), Ef6.2 (MK721188), Ef6.3 (MK721196), Ef6.4 628 
(MK721190), Ef7.1 (MK721194), Ef7.2 (MK721183), Ef7.3 (MK721184) and Ef7.4 629 
(MK721198). 630 
Genetic maps of bacteriophage genomes were generated by LinearDisplay.pl 631 
(https://github.com/JCVenterInstitute/LinearDisplay), a PERL script that uses Xfig 632 
(https://sourceforge.net/projects/mcj/) to render high-quality images. Preliminary 633 
annotation of genes was derived from the automated annotation and from 634 
Phage_Finder42, which uses curated HMMs and databases of core phage gene to 635 
annotate core gene functions. Annotation was then manually reviewed to assign the final 636 
colors. 637 
 638 
Bacteriophage phylogenetic tree. A phage whole genome phylogeny tree was 639 
generated from a pairwise distance matrix calculated with the MASH program, which 640 
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approximates average nucleotide identity (ANI)43. First, a sketch file was created from all 641 
the 19 E. faecalis phage genomes isolated and sequenced in this study plus 54 642 
Enterococcus phage genomes obtained from GenBank, with 5000 12mers generated per 643 
genome (mash sketch -k 12 -s 5000). The sketch file was then compared to all the initial 644 
phage genome sequences to generate the ANI matrix using the mash distance command 645 
using default settings. The GGRaSP R-package was used to calculate the UPMGA 646 
phylogeny from the ANI distance matrix, after redundant phage genomes (genomes ANI > 647 
99.985) were removed using the GGRaSP R-package with a user defined cutoff of 0.015 648 
(ggrasp.cluster (threshold = 0.015)). The resulting dendrogram was translated into newick 649 
format using the APE R package44, loaded into the iTOL tree viewer45, and annotated with 650 
taxonomic information and manually-entered clade identification. 651 
 652 
Electron microscopy. Bacteriophage morphology was examined by transmission 653 
electron microscopy of negatively stained grids, prepared using the valentine method46 654 
with either 2% uranyl-acetate or 2% phosphotungstic acid, and examined at an 655 
acceleration voltage of 100KV in the JEOL 1200 EX Transmission Electron Microscope.  656 
 657 
Bacterial DNA extraction and 16S rRNA sequencing. DNA from human stool samples, 658 
mouse liver sections or bacterial culture was extracted as described before11, and DNA 659 
from mouse feces was extracted using QIAamp Fast DNA Stool kit (QIAGEN). 16S 660 
ribosomal RNA (rRNA) PCR was completed using Illumina adaptor and barcode ligated 661 
16S primers targeting the V4 region of the 16S rRNA gene47,48. Amplicons were purified 662 
using the Qiaquick PCR purification kit (QIAGEN) using manufacturer’s specifications. 663 
Purified amplicons were then quantified via TECAN assay (Tecan, Switzerland), 664 
normalized, and pooled in preparation for 16S rRNA sequencing. Pooled library was 665 
quantified and checked for quality using Agilent 2100 Bioanalyzer (Agilent Technologies). 666 
Library was sequenced on Illumina MiSeq (Illumina) using V2 reagent chemistry, 500 667 
cycles, 2 x 250bp format using manufacturer’s specifications. 16S sequence reads were 668 
processed and OTUs were determined using our MOTHUR-based 16S rDNA analysis 669 
workflow as described previously11,49. Raw 16S sequence reads can be found in the NCBI 670 
SRA associated with Bioproject PRJNA525701.   671 
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 672 
Real-time quantitative PCR. Bacterial genomic DNA was extracted from human stool 673 
samples and mouse liver11. RNA was extracted from mouse liver and cDNAs were 674 
generated11. Primer sequences for mouse genes were obtained from the NIH 675 
qPrimerDepot. Primer sequences for E. faecalis 16S rRNA gene, E. faecalis cylLS and 676 
cylLL genes were described before50,51. All primers used in this study are listed in 677 
Supplementary Table 9. Mouse gene expression and amplification of bacterial genes 678 
were determined with Sybr Green (Bio-Rad Laboratories) using ABI StepOnePlus real-679 
time PCR system. The qPCR value of mouse genes was normalized to 18S. 680 
 681 
E. faecalis isolation and whole-genome sequencing. To isolate E. faecalis strains from 682 
human subjects, 50–300 mg of human stool was resuspended in 500 μl PBS, serial 683 
dilutions were made, and 100 μl was placed on plates with selective medium, BBL 684 
Enterococcosel broth (Becton Dickinson). Enterococci colonies were identified by the 685 
production of dark brown or black color generated by hydrolysis of esculin to esculetin 686 
that reacts with ferric ammonium citrate. Each Enterococcus colony was then picked, and 687 
qPCR was performed to identify E. faecalis, using specific primers against the E. faecalis 688 
16S rRNA gene50. For each subject, 1 – 6 E. faecalis colonies were analyzed and bacterial 689 
genomic DNA was then extracted as described in above section.  690 
DNA sequencing was performed on the Illumina HiSeq Ten X generating paired-end 691 
reads (2 x 151bp). Bacterial genomes were assembled and annotated using the pipeline 692 
described previously52. Antimicrobial resistance and virulence genes including cytolysin 693 
(cyl) genes carried by E. faecalis isolates were identified by comparing individual genome 694 
assemblies against the CARD and VFDB databases using abricate v0.8.10 695 
(https://github.com/tseemann/abricate), respectively53,54. 696 
For the phylogeny of E. faecalis, the genome assemblies of the study isolates were 697 
annotated with Prokka55, and a pangenome estimated using Roary52. A 95% identity cut-698 
off was used, and core genes were defined as those in 99% of isolates. A maximum 699 
likelihood tree of the SNPs in the core genes was created using RAxML56 and 100 700 
bootstraps. The resulting tree was visualized using iTOL45. Genome sequence data of E. 701 
faecalis strains isolated in this study have been deposited in the European Nucleotide 702 
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Archive (ENA) under the accession number PRJEB25007. Sequence reads are available 703 
at ENA under Run accession IDs ERR3200171-ERR3200263. 704 
 705 
E. faecalis culture. All E. faecalis strains were grown statically in brain heart infusion 706 
(BHI) broth or on BHI agar plate at 37°C. 50 μg/ml erythromycin was added when cytolytic 707 
and non-cytolytic E. faecalis strains were grown (Extended Data Figure 2). 708 
 709 
Fecal Enterococcus level determination. To determine fecal enterococci level in mice, 710 
10–30 mg of mouse feces was resuspended into 500 μl PBS and serial dilutions were 711 
made. Five microliters of each dilution from each sample were spotted onto a plate with 712 
a selective medium, BBL Enterococcosel broth (Becton Dickinson) and the plates were 713 
then incubated at 37°C overnight. For Extended Data Fig. 2o, agar plates contained 50 714 
μg/ml erythromycin. Enterococci colonies were identified by the production of dark brown 715 
or black color generated by hydrolysis of esculin to esculetin that reacts with ferric 716 
ammonium citrate. Colony numbers of each sample were then counted and CFUs were 717 
calculated. 718 
 719 
Cytolysin expression and purification. To purify bioactive CylLL” and CylLS”, an E. coli 720 
heterologous expression system was used. Briefly, either Hisx6-CylLL or Hisx6-CylLS 721 
were co-expressed with CylM (enzyme that performs dehydration and cyclization 722 
reactions on cytolysin) in E. coli to yield fully dehydrated and cyclized full-length peptides. 723 
The His-tag and leader peptide were then removed using recombinant CylA (27-412), the 724 
soluble domain of the native peptidase used in cytolysin maturation, to yield bioactive 725 
CylLL” or CylLS”. The resulting core peptides were further purified by reversed-phase 726 
HPLC.  727 
The cylLL and cylLS genes were previously cloned into the MCSI of a pRSFDuet-1 728 
backbone vector which contained the cylM gene in MCSII6. The cylA (27–412) gene was 729 
previously cloned into MCSI of a pRSFDuet-1 backbone vector57. E. coli BL21 Star™ 730 
(DE3) cells (50 µl) were transformed with 100 ng of either the cylLL_cylM:pRSFDuet, 731 
cylLS_cylM:pRSFDuet or cylA (27-412):pRSFDuet plasmids via KCM chemical 732 
transformation. The cells were plated on LB agar plates supplemented with kanamycin 733 
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(50 µg/ml) and grown at 37°C overnight. One colony was picked to inoculate 15 ml of LB 734 
broth supplemented with kanamycin overnight at 37°C. The culture was used to inoculate 735 
1.5 liters of terrific broth supplemented with kanamycin. Cultures were grown with shaking 736 
at 37°C to an OD600 of 0.8. The temperature of the incubator was lowered to 18°C and 737 
expression was induced with the addition of 0.3 mM final concentration of isopropyl β-D-738 
thiogalactoside. The cultures were allowed to incubate at 18°C for 18 hours. The cells 739 
were collected by centrifugation at 5000 x g for 12 min. The cell paste was collected and 740 
frozen at -70°C.   741 
For the purification of the protease CylA (27–412), the cell paste was thawed and 742 
resuspended in 50 ml LanP buffer (20 mM HEPES, 1 M NaCl, pH 7.5). The cell 743 
suspension was lysed by homogenization. The lysate was clarified by centrifugation at 744 
13,000 x g for 45 min and filtered through a 0.45 µm centrifugal filter (Thermo Scientific). 745 
The clarified lysate was applied to a pre-equilibrated HisTrap HP 5 ml column (GE 746 
Healthcare) through a peristaltic pump. The loaded column was connected to an ÄKTA 747 
pure 25 M system. The protein was eluted by a linear gradient of LanP buffer to Elution 748 
Buffer (20 mM HEPES, 1 M NaCl, 500 mM imidazole, 10% glycerol, pH 7.5) over 30 min. 749 
The purest fractions, as determined by 4%–20% SDS-PAGE, were combined, 750 
concentrated to 1 mg/ml by Amicon Ultra Centrifugal Filters (30 kDa MWCO), and buffer 751 
exchanged into storage buffer (20mM HEPES, 300 mM KCl, 10% glycerol, pH 7.5) by 752 
PD-10 desalting column (GE Healthcare). Protein concentration was determined by 753 
absorbance at 280 nm.   754 
For the purification of CylLL” and CylLS” peptides, the cell paste was thawed and 755 
resuspended in 50 ml of LanA Buffer B1 (6 M guanidine HCl, 20 mM NaH2PO4, 500 mM 756 
NaCl, 0.5 mM imidazole, pH 7.5). The cell suspension was lysed via sonication (2 sec 757 
pulse on, 5 sec pulse off, 7 min total pulse on time). The cell lysate was clarified by 758 
centrifugation at 13,000 x g for 45 min. The clarified cell lysate was filtered through a 0.45 759 
µm centrifugal filter and applied via gravity flow to a pre-equilibrated, 2 ml bed volume of 760 
His60 Ni Superflow Resin (Clonetech). After the lysate had been applied, the resin was 761 
washed with 15 ml of LanA Buffer B2 (4 M guanidine HCl, 20 mM NaH2PO4, 500 mM 762 
NaCl, 30 mM imidazole, pH 7.5). The resin was washed again with 15 ml of LanA Wash 763 
Buffer (20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5) to remove the 764 
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guanidine HCl. The peptides were eluted with 10 ml of LanA Elution Buffer (20 mM 765 
NaH2PO4, 500 mM NaCl, 500 mM imidazole, pH 7.5). A 0.02 mg/ml final concentration of 766 
CylA (27–412) was added to the elution fraction and allowed to incubate at room 767 
temperature overnight to remove the leader peptide.  768 
The digestion was quenched by adding 2% (v/v) final concentration of trifluoroacetic 769 
acid. The solution was centrifuged at 4,500 x g for 10 min and filtered through a 0.45 µm 770 
syringe filter (Thermo Scientific). The core peptides were purified by semi-preparative 771 
reverse phase HPLC using a Phenomenex Jupiter Proteo column (10 mm x 250 mm, 4 772 
µm, 90 Å) connected to an Agilent 1260 Infinity II liquid chromatography system. The 773 
peptides were separated using a linear gradient of 3% (v/v) solvent B (acetonitrile + 0.1% 774 
trifluoroacetic acid) in solvent A (water + 0.1% trifluoroacetic acid). The fractions were 775 
spotted on a MALDI target plate by mixing 1 µl of sample with 1µl of a 25 mg/ml solution 776 
of Super-DHB (Sigma) in 80% acetonitrile/water + 0.1% trifluoroacetic acid. The fractions 777 
were analyzed by MALDI-TOF MS on a Bruker UltrafleXtreme MALDI-TOF/TOF operating 778 
in positive ionization, reflector mode.  779 
 780 
Primary mouse hepatocytes. Hepatocytes were isolated from C57BL/6 female mice fed 781 
the chronic–binge ethanol diet (NIAAA model)15. Livers were perfused in situ with 0.5 mM 782 
EGTA containing calcium-free salt solution and then perfused with a solution containing 783 
0.02% (w/v) collagenase D (Roche Applied Science). Livers were then carefully minced 784 
and filtered using a 70 μm nylon cell strainer. Hepatocytes were centrifuged at 50 x g for 785 
1 min after three times washing. Hepatocyte viability was assessed by Trypan Blue 786 
(Thermo Fisher Scientific). 1.5 × 105 hepatocytes were seeded on 12-well plates coated 787 
with rat collagen type I in DMEM-F12 (Thermo Fisher Scientific) with insulin-transferrin-788 
selenium (1% v/v) (Thermo Fisher Scientific) and 40 ng/ml dexamethasone (MP 789 
Biomedicals) containing 10% (v/v) fetal bovine serum (FBS; Gemini Bio-Products) and 790 
antibiotics. After 4 hours, the culture was washed with DMEM-F12 media and changed to 791 
the same complemented media without FBS58. Then 16 hours later, hepatocytes were 792 
cultured with 0 or 25 mM ethanol and stimulated with 0, 200 or 400 nM CylLS” and/or 793 
CylLL” in the same culture medium without FBS. After 3 hours stimulation, hepatocyte 794 
cytotoxicity was assessed using Pierce LDH Cytotoxicity Detection Kit (Thermo Fisher 795 
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Scientific).  796 
 797 
Biochemical analysis. Serum levels of ALT were determined using Infinity ALT kit 798 
(Thermo Scientific). Hepatic triglyceride levels were measured using Triglyceride Liquid 799 
Reagents kit (Pointe Scientific). Levels of serum LPS and fecal albumin were determined 800 
by ELISA kits (Lifeome Biolabs and Bethyl Labs, respectively). Serum levels of ethanol 801 
were measured using Ethanol Assay kit (BioVision). 802 
 803 
Staining procedures. Formalin-fixed tissue samples were embedded in paraffin and 804 
stained with hematoxylin-eosin. To determine lipid accumulation, liver sections were 805 
embedded in OCT compound. 8 μm frozen sections were then cut and stained with Oil 806 
Red O (Sigma-Aldrich). Representative pictures from each group of mice were shown in 807 
each figure. The terminal deoxynucleotide transferase-mediated dUTP nick-end labeling 808 
(TUNEL) assay was performed using an in situ cell death detection kit (Sigma-Aldrich). 809 
We randomly selected five high-power fields for counting TUNEL-positive cells and 810 
normalized numbers to total cells. 811 
 812 
Data availability. Raw 16S sequence reads can be found in the NCBI SRA associated 813 
with Bioproject PRJNA525701. Bacteriophage raw sequence reads and annotated 814 
genomes are available at NCBI under the following consecutive BioSample IDs 815 
(SAMN11089809 – SAMN11089827). Genome sequence data of E. faecalis strains 816 
isolated in this study were registered at ENA under Study PRJEB25007.  817 
 818 
Code availability. The PERL script for making the genetic maps of bacteriophage 819 
genomes can be found at https://github.com/JCVenterInstitute/LinearDisplay. 820 
 821 
Statistical analysis. Results are expressed as mean ± s.e.m. (except when stated 822 
otherwise). Univariate and multivariate Cox regression analysis was used to detect 823 
associations of cytolysin with overall mortality. The multivariate model was adjusted for 824 
geographic origin of the patients; antibiotic treatment; platelet count; and creatinine, 825 
bilirubin and INR as components of the MELD score. Univariate logistic regression 826 
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analysis of laboratory and clinical parameters associated with the detection of cytolysin 827 
and E. faecalis was performed. Univariate linear regression analysis of laboratory and 828 
clinical parameters associated with the log-transformed total amount of fecal E. faecalis 829 
measured with qPCR was performed. To associate log-transformed total E. faecalis and 830 
E. faecalis positivity with mortality, univariate Cox regression was used. P values from 831 
Univariate and Multivariate Cox regression, Univariate logistic regression and Univariate 832 
linear regression were determined by Wald test. Multicollinearity was examined using the 833 
variance inflation factor (VIF). Kaplan-Meier curves were used to compare survival 834 
between cytolysin-positive and cytolysin-negative alcoholic hepatitis patients. Fecal E. 835 
faecalis, bacterial diversity and richness from controls and patients were compared using 836 
Kruskal-Wallis test with Dunn’s post-hoc test. Region/center specific clinical 837 
characteristics of alcoholic hepatitis patients were compared with Kruskal-Wallis test for 838 
continuous and Fisher’s exact test for categorical variables. Fecal E. faecalis in alcoholic 839 
hepatitis patients with or without cytolysin, and with or without cirrhosis, were compared 840 
with Mann-Whitney-Wilcoxon rank-sum test. Fecal E. faecalis in alcoholic hepatitis 841 
patients from different region/centers were compared with Kruskal-Wallis test. 842 
Percentage of subjects with fecal samples positive for E. faecalis and cytolysin was 843 
compared using Fisher’s exact test, followed by FDR procedures for multiple group 844 
comparisons. Jaccard dissimilarity matrices were used for principal coordinate analysis 845 
(PCoA) and P values were determined by permutational multivariate analysis of variance 846 
(PERMANOVA) followed by FDR procedures to correct for multiple comparisons.  847 
For mouse and cell culture studies, significance of multiple groups was evaluated 848 
using one-way or two-way analysis of variance (ANOVA) with Tukey’s post-hoc test. 849 
Fisher’s exact test was used in the analysis of liver E. faecalis and cytolysin with FDR 850 
correction for multiple comparisons. Kaplan-Meier curves were used to compare survival 851 
between experimental mouse groups. PCoA based on Jaccard dissimilarity matrices was 852 
performed between experimental mouse groups and the P values were determined by 853 
PERMANOVA followed by FDR procedures to correct for multiple comparisons. 854 
Exact P values for all comparisons, together with group size for each group, were 855 
listed in Supplementary Table 10. Statistical analyses were performed using R statistical 856 
software, R version 3.5.1, 2018 the R Foundation for Statistical Computing and GraphPad 857 
32 
 
Prism v6.01. A P < 0.05 was considered to be statistically significant (adjusted for multiple 858 
comparison when performing multiple tests).  859 
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Extended Data Figure Legends 935 
Extended Data Figure 1. Intestinal dysbiosis in patients with alcoholic hepatitis.  936 
(a) 16S rRNA sequencing of fecal samples from controls (n=14), patients with alcohol use 937 
disorder (AUD; n=43), or alcoholic hepatitis (n=75). The graph demonstrates the relative 938 
abundance of sequence reads in each genus. (b) Bacterial diversity (Shannon-Index and 939 
Simpson-Index) and richness (Chao-Richness) was calculated in controls (n=14), 940 
patients with AUD (n=43), or alcoholic hepatitis (n=75). (c) E. faecalis in fecal samples 941 
from controls (n=25), patients with AUD (n=38), or alcoholic hepatitis (n=82), assessed 942 
by qPCR. (d) Percentage of fecal samples positive for E. faecalis in controls (n=25), 943 
patients with AUD (n=38), or alcoholic hepatitis (n=82), assessed by qPCR. E. faecalis 944 
was detected in feces from 80% of patients with alcoholic hepatitis vs 36% of controls 945 
(P<0.001). There was also a significant difference between patients with alcohol use 946 
disorder and alcoholic hepatitis (P<0.01). (e) ROC curves and AUC for the comparison of 947 
90-day mortality and cytolysin positivity (red; n=57), MELD score (blue; n=56), ABIC score 948 
(yellow; n=57), and DF (green; n=42) in patients with alcoholic hepatitis. (f) E. faecalis in 949 
fecal samples from patients with alcoholic hepatitis whose fecal samples were cytolysin 950 
positive (n=25) or cytolysin negative (n=54), assessed by qPCR (P=0.8174). (g) 16S 951 
rRNA sequencing of fecal samples from patients with alcoholic hepatitis from different 952 
centers (France n=9; Mexico n=6; Spain n=5; UK n=11; USA East n=16; USA Midwest 953 
n=12; USA West n=16). Principal coordinate analysis (PCoA) based on Jaccard 954 
dissimilarity matrices was used to show ß-diversity among groups, at the genus level. 955 
Composition of fecal microbiota was significantly different (P<0.01). (h) Percentage of 956 
fecal samples positive for cylLL and cylLS DNA sequences (cytolysin-positive), in patients 957 
with alcoholic hepatitis from different centers (France n=16; Mexico n=6; Spain n=6; UK 958 
n=10; USA East n=16; USA Midwest n=13; USA West n=15), assessed by qPCR 959 
(P=0.6094). (i) E. faecalis in fecal samples from patients with alcoholic hepatitis from 960 
different centers, assessed by qPCR (P=0.5648). (j) Percentage of fecal samples positive 961 
for E. faecalis in patients with alcoholic hepatitis from different centers (France n=16; 962 
Mexico n=6; Spain n=6; UK n=10; USA East n=16; USA Midwest n=13; USA West n=15), 963 
assessed by qPCR (P=0.0529). (k) Percentage of subjects with fecal samples positive for 964 
cylLL and cylLS DNA sequences (cytolysin positive), in patients with alcoholic hepatitis and 965 
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cirrhosis (n=30), or without cirrhosis (n=18), assessed by qPCR (P=0.3431). (l) E. faecalis 966 
in fecal samples from patients with alcoholic hepatitis and cirrhosis (n=30), or without 967 
cirrhosis (n=18), assessed by qPCR (P=0.5736). (m) Percentage of fecal samples 968 
positive for E. faecalis in alcoholic hepatitis patients with cirrhosis (n=30), or without 969 
cirrhosis (n=18), assessed by qPCR (P=0.2878). Results are expressed as as mean ± 970 
s.e.m (c, f, i, l). For the Box and Whisker plots in (b), the box extends from 25th to 75th 971 
percentiles, with the center line representing the median; for all three groups, the lower 972 
whiskers show the minimum values; for the “Controls” group (black), the higher whisker 973 
shows the maximum value; for the other two groups, the higher whiskers represent the 974 
75th percentile plus 1.5 times inter-quartile distance (the distance between the 25th and 975 
75th percentiles), all values greater than this are plotted as individual dots. P values are 976 
determined by Kruskal-Wallis test (i) with Dunn’s post-hoc test (b, c), two-sided Fisher’s 977 
exact test (h, j, k, m) followed by false discovery rate (FDR) procedures (d), two-sided 978 
Mann-Whitney-Wilcoxon rank-sum test (f, l), or permutational multivariate analysis of 979 
variance (PERMANOVA) (g). The exact group size (n) and P values for each comparison 980 
are listed in Supplementary Table 10. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 981 
 982 
Extended Data Figure 2. Cytolytic E. faecalis causes progression of ethanol-983 
induced liver disease in mice.  984 
(a–n) C57BL/6 mice were fed oral isocaloric (control) or chronic–binge ethanol diets and 985 
gavaged with vehicle (PBS), a cytolytic E. faecalis strain (FA2-2(pAM714)) (E. faecalis) 986 
(5x108 colony forming units (CFUs)), or a non-cytolytic E. faecalis strain (FA2-987 
2(pAM771))5 (E. faecalis cytolysin) (5x108 CFUs) every third day. (a) Serum levels of 988 
ALT. (b) Hepatic triglyceride content. (c) Representative oil red O-stained liver sections. 989 
(d–f) Hepatic levels of mRNAs. (g) Kaplan-Meier curve of survival of mice on chronic–990 
binge ethanol diets (day 0, start of ethanol feeding). Mice gavaged with PBS all survived 991 
and were not included in figure. A higher proportion of mice (n=15) gavaged with non-992 
cytolytic E. faecalis survived than mice (n=25) gavaged with cytolytic E. faecalis. (h) 993 
Proportions of mice positive for cytolysin in liver, measured by qPCR for cylLS (the gene 994 
encoding cytolysin subunit CylLS”). (i) Proportions of mice positive for E. faecalis in liver, 995 
measured by qPCR. About 80% of mice colonized with cytolytic E. faecalis, as well as 996 
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non-cytolytic E. faecalis, were positive for E. faecalis in their livers. (j) Liver CFUs of 997 
Enterococcus in mice on a chronic–binge ethanol diet. (k) Paracellular intestinal 998 
permeability was evaluated by measuring fecal albumin content and serum levels of 999 
lipopolysaccharide (LPS) by ELISAs. (l) Fecal samples were collected and 16S rRNA 1000 
genes were sequenced. Principal coordinate analysis based on Jaccard dissimilarity 1001 
matrices showed no significant differences among mice gavaged with PBS, cytolytic or 1002 
non-cytolytic E. faecalis following the diets. Compared to control-diet fed mice, mice fed 1003 
with ethanol diet had significant different fecal microbiomes after gavaging E. faecalis 1004 
(P<0.05). (m and n) Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 1005 
mRNAs did not differ significantly among these mice after ethanol feeding. (o) Mice were 1006 
gavaged with cytolytic or non-cytolytic E. faecalis strains (carrying erythromycin 1007 
resistance gene; 5x108 CFUs) at time 0, and feces was collected at 0, 8, 24, 48, and 72 1008 
hrs. Fecal CFUs of Enterococcus were determined by culturing fecal samples on BBL 1009 
Enterococcosel Broth agar plate with 50 μg/ml erythromycin. At time 0 and 72, 5/5 and 1010 
4/5 mice, respectively, had no detectable erythromycin-resistant Enterococcus in feces. 1011 
These points are not shown on the graph, but have been included in the calculation of 1012 
mean ± s.e.m. Scale bar=100 μm. Results are expressed as mean ± s.e.m (a, b, d–f, j, k, 1013 
m–o). P values among groups of mice fed with control diet or ethanol diet are determined 1014 
by One-way ANOVA with Tukey´s post-hoc test (a, b, d–f, j, k, m, n), two-sided Log-rank 1015 
(Mantel-Cox) test (g), two-sided Fisher’s exact test followed by FDR procedures (h and 1016 
i), or PERMANOVA followed by FDR procedures (l). All results were generated from at 1017 
least three independent replicates. The exact group size (n) and P values for each 1018 
comparison are listed in Supplementary Table 10. P values between control-diet fed mice 1019 
and ethanol-diet fed mice are determined by Two-way ANOVA (k). *P<0.05, **P<0.01, 1020 
***P<0.001, ****P<0.0001. 1021 
 1022 
Extended Data Figure 3. Transplantation of cytolysin-positive feces increases 1023 
ethanol-induced liver disease in gnotobiotic mice.  1024 
(a–f, h, i) C57BL/6 germ-free mice were colonized with feces from two different cytolysin-1025 
positive and two different cytolysin-negative patients with alcoholic hepatitis, and then fed 1026 
isocaloric (control) or chronic–binge ethanol diets. (a) Percentage of terminal 1027 
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deoxynucleotide transferase-mediated dUTP nick-end labeling (TUNEL) positive hepatic 1028 
cells. (b) Representative oil red O-stained liver sections. (c and d) Hepatic levels of 1029 
mRNAs encoding the inflammatory cytokine Cxcl2, and Acta2 (marker of activated 1030 
hepatic stellate cells). (e) Kaplan-Meier curve of survival of mice on chronic–binge ethanol 1031 
diets (day 0, start of ethanol feeding) gavaged with feces from cytolysin-positive (n=48 1032 
mice) or cytolysin-negative (n=32 mice) patients with alcoholic hepatitis. (f) Fecal samples 1033 
were collected and 16S rRNA genes were sequenced. The graph shows principal 1034 
coordinate analysis of fecal microbiomes. No significant difference was observed 1035 
between mice colonized with feces from cytolysin positive or negative alcoholic hepatitis 1036 
donors following the control diet. Mice transplanted with feces from cytolysin-positive 1037 
alcoholic hepatitis patient #2 showed a significantly different microbiota than the other 1038 
mouse groups following ethanol administration (P<0.01). (g) Percentage of cytolysin-1039 
positive E. faecalis in 4 patients with alcoholic hepatitis. Stool samples from the four 1040 
patients were placed on plates with selective medium and Enterococcus colonies were 1041 
identified by the production of dark brown or black color generated by hydrolysis of esculin 1042 
to esculetin that reacts with ferric ammonium citrate. Enterococcus colonies were 1043 
confirmed to be E. faecalis by qPCR. Cytolysin status of each E. faecalis colony was 1044 
determined by qPCR. (h) Serum levels of ethanol were comparable among colonized 1045 
mice after ethanol feeding. (i) Hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ 1046 
significantly among colonized mice on control or ethanol diets. Scale bar=100 μm. Results 1047 
are expressed as mean ± s.e.m (a, c, d, h, i). P values are determined by One-way ANOVA 1048 
with Tukey´s post-hoc test (a, c, d, h, i), two-sided Log-rank (Mantel-Cox) test (e), or 1049 
PERMANOVA followed by FDR procedures (f). All results were generated from at least 1050 
three independent replicates. The exact group size (n) and P values for each comparison 1051 
are listed in Supplementary Table 10. *P<0.05, **P<0.01, ***P<0.001. 1052 
 1053 
Extended Data Figure 4. Isolation and amplification of bacteriophages against 1054 
cytolytic E. faecalis isolated from mice.  1055 
(a) BHI agar plate showing bacteriophage plaque morphology. Bacteriophage cocktail 1056 
(100 μl, 102–103 PFUs) was mixed with overnight grown E. faecalis culture (100 μl) and 1057 
then added to BHI broth top agar (0.5% agar) and poured over a BHI plate (1.5% agar). 1058 
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After overnight growth at 37°C, images were captured on an Epson Perfection 4990 Photo 1059 
scanner. (b) Simplified illustration of different bacteriophage morphology. Siphophages 1060 
have long, flexible, noncontractile tails (left), myophages have contractile tails (middle), 1061 
and podophages have short, noncontractile tails (right). (c) Transmission electron 1062 
microscopy revealed that bacteriophages isolated were all podophages (Efmus1, 1063 
Efmus2, Efmus3 and Efmus4). Phages specific to E. faecalis strain isolated from mouse 1064 
feces were named as Efmus with a number (Ef for E. faecalis, mus for mouse, digit for 1065 
isolation order). (d) Genetic map of phage genomes. The linear maps are based on 1066 
nucleotide sequences of the phage genomes and predicted open reading frames. The 1067 
name and length (bp) of each genome are indicated to the left of each phage map. 1068 
Protein-coding sequences are colored based on functional role categories (see box). 1069 
Scale bar=50 nm. All results were generated from at least three independent replicates.  1070 
 1071 
Extended Data Figure 5. Phages reduce translocation of cytolysin to the liver and 1072 
reduce ethanol-induced liver disease in Atp4aSl/Sl mice. 1073 
(a–k) Wild-type (WT) and their Atp4aSl/Sl littermates were fed oral isocaloric (control) or 1074 
chronic–binge ethanol diets and gavaged with vehicle (PBS), control phages against C. 1075 
crescentus (1010 plaque forming units (PFUs)), or a cocktail of 4 different phages targeting 1076 
cytolytic E. faecalis (1010 PFUs) 1 day before ethanol binge. (a) Serum levels of ALT. (b) 1077 
Hepatic triglyceride content. (c) Representative oil red O-stained liver sections. (d–f) 1078 
Hepatic levels of mRNAs. (g) Proportions of mice positive for cytolysin in liver, measured 1079 
by qPCR for cylLS. (h) Fecal colony forming units (CFUs) of Enterococcus. (i) Fecal 1080 
samples were collected and 16S rRNA genes were sequenced. Principal coordinate 1081 
analysis based on Jaccard dissimilarity matrices found no significant difference in fecal 1082 
microbiota among mice given PBS, control phage, or phages targeting cytolytic E. faecalis 1083 
in each group. (j and k) Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 1084 
mRNAs did not differ significantly among colonized mice after ethanol feeding. Scale 1085 
bar=100 μm. Results are expressed as mean ± s.e.m (a, b, d–f, h, j, k). P values are 1086 
determined by Two-way ANOVA with Tukey´s post-hoc test (a, b, d–f, h, j, k), two-sided 1087 
Fisher’s exact test followed by FDR procedures (g), or PERMANOVA followed by FDR 1088 
procedures (i). All results were generated from at least three independent replicates. The 1089 
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exact group size (n) and P values for each comparison are listed in Supplementary Table 1090 
10. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 1091 
 1092 
Extended Data Figure 6. Isolation and amplification of bacteriophages against 1093 
cytolytic E. faecalis isolated from patients with alcoholic hepatitis.  1094 
(a) BHI agar plates showing bacteriophage plaque morphology. (b) Transmission electron 1095 
microscopy graphs of myophages Ef2.1 and Ef2.3, stained with phosphotungstic acid 1096 
showing contracted tails. (c) Genetic map of phage genomes. The linear maps are based 1097 
on nucleotide sequences of the phage genomes and predicted open reading frames. The 1098 
name and length (bp) of each genome are indicated to the left of each phage map. 1099 
Protein-coding sequences are colored based on functional role categories (see box). 1100 
Sequences encoding tRNA genes are indicated by a cloverleaf structure. Scale bar=50 1101 
nm. All results were generated from at least three independent replicates. 1102 
 1103 
Extended Data Figure 7. Phages that target cytolytic E. faecalis reduce ethanol-1104 
induced liver disease in gnotobiotic mice.  1105 
(a–h) C57BL/6 germ-free mice were colonized with feces from two different cytolysin-1106 
positive patients with alcoholic hepatitis (feces from 1 patient is used in Figure 2). The 1107 
mice were then fed oral isocaloric (control) or chronic–binge ethanol diets, and gavaged 1108 
with control phages against C. crescentus (1010 plaque forming units (PFUs)), or a 1109 
cocktail of 3 or 4 different phages targeting cytolytic E. faecalis (1010 PFUs) 1 day before 1110 
an ethanol binge. (a) Percentage of TUNEL-positive hepatic cells. (b) Representative oil 1111 
red O-stained liver sections. (c and d) Hepatic levels of mRNAs encoding the 1112 
inflammatory cytokine Cxcl2, and Acta2 (marker of activated hepatic stellate cells). (e) 1113 
Fecal colony forming units (CFUs) of Enterococcus. (f) Fecal samples were collected and 1114 
16S rRNA genes were sequenced. Principal coordinate analysis based on Jaccard 1115 
dissimilarity matrices shows no significant differences in fecal microbiota of mice gavaged 1116 
with control phage and phages targeting cytolytic E. faecalis in each group. (g and h) 1117 
Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not differ 1118 
significantly among colonized mice after ethanol feeding. Scale bar=100 μm. Results are 1119 
expressed as mean ± s.e.m (a, c–e, g, h). P values are determined by Two-way ANOVA 1120 
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with Tukey´s post-hoc test (a, c–e, g, h), or PERMANOVA followed by FDR procedures 1121 
(f). All results were generated from at least three independent replicates. The exact group 1122 
size (n) and P values for each comparison are listed in Supplementary Table 10. *P<0.05, 1123 
***P<0.001. 1124 
 1125 
Extended Data Figure 8. Isolation and amplification of bacteriophages against non-1126 
cytolytic E. faecalis isolated from patients with alcoholic hepatitis.  1127 
(a) BHI agar plates showing bacteriophage plaque morphology. (b) Genetic map of phage 1128 
genomes. The linear maps are based on nucleotide sequences of the phage genomes 1129 
and predicted open reading frames. The name and length (bp) of each genome are 1130 
indicated to the left of each phage map. Protein-coding sequences are colored based on 1131 
functional role categories (see box). Sequences encoding tRNA genes are indicated by a 1132 
cloverleaf structure. (c) Phylogenetic tree of Enterococcus bacteriophages. A whole-1133 
genome average nucleotide distance tree was constructed for 73 available Enterococcus 1134 
phage genomes, 54 from GenBank (black letters), 19 from this study (4 phages against 1135 
cytolysin-positive E. faecalis isolated from mice in blue letters, 7 phages against cytolysin-1136 
positive E. faecalis isolated from alcoholic hepatitis patients in pink letters, and 8 phages 1137 
against cytolysin-negative E. faecalis isolated from alcoholic hepatitis patients in green 1138 
letters) with Mash43 using a sketch size of s=5000 and k-mer size of k=12 and GGRaSP59 1139 
(see Methods). Colored branches denote specific phage genera: Sap6virus, P68virus and 1140 
Spounavirinae. The scale bar represents percent average nucleotide divergence. All 1141 
results were generated from at least three independent replicates. 1142 
 1143 
Extended Data Figure 9. Phages that target non-cytolytic E. faecalis do not reduce 1144 
ethanol-induced liver disease in gnotobiotic mice.  1145 
(a–h) C57BL/6 germfree mice were colonized with feces from two different cytolysin-1146 
negative patients with alcoholic hepatitis. Transplanted gnotobiotic mice were fed oral 1147 
isocaloric (control) or chronic–binge ethanol diets and gavaged with control phages 1148 
against C. crescentus (1010 plaque forming units (PFUs)), or a cocktail of 4 different 1149 
phages targeting non-cytolytic E. faecalis (1010 PFUs) 1 day before an ethanol binge. (a) 1150 
Percentage of TUNEL-positive hepatic cells. (b) Representative oil red O-stained liver 1151 
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sections. (c and d) Hepatic levels of mRNAs encoding the inflammatory cytokine Cxcl2, 1152 
and Acta2 (marker of activated hepatic stellate cells). (e) Proportions of mice positive for 1153 
cytolysin in liver, measured by qPCR for cylLS. (f) Fecal samples were collected and 16S 1154 
rRNA genes were sequenced. Principal coordinate analysis based on Jaccard 1155 
dissimilarity matrices found no significant difference in fecal microbiota among mice 1156 
gavaged with control phages and phages targeting cytolytic E. faecalis in each group. (g 1157 
and h) Serum levels of ethanol and hepatic levels of Adh1 and Cyp2e1 mRNAs did not 1158 
differ significantly among colonized mice after ethanol feeding. Scale bar=100 μm. 1159 
Results are expressed as mean ± s.e.m (a, c, d, g, h). P values are determined by Two-1160 
way ANOVA with Tukey´s post-hoc test (a, c, d, g, h), two-sided Fisher’s exact test 1161 
followed by FDR procedures (e), or PERMANOVA followed by FDR procedures (f). All 1162 
results were generated from at least three independent replicates. The exact group size 1163 
(n) and P values for each comparison are listed in Supplementary Table 10.  1164 
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